Novavax is trading at $10.39, up 5.32%; available context does not identify a specific cause for the intraday rebound. - Shares are rebounding after a November 5 close down 8.17%, as investors weighed lower year-over-year revenue and a profitability target pushed to 2029. - The quarter beat revenue expectations, and Novavax raised its 2026 adjusted revenue outlook to $385M–$415M, largely reflecting a $125M Sanofi milestone. - Market context points to a broader November 6 tech-market recovery.